Mutation; T-cell-receptor gene; hypoxanthine-phosphoribosyltransferase gene; chromosome aberrations; flow cytometry; radiotherapy Dose estimates for the assessment of future risks, following accidental exposure to radiation, for certain diseases such as cancer usually rely on both physical and biological quantitative analyses. A traditional biological method of choice is the measurement of chromosome aberration frequencies in peripheral-blood lymphocytes. However, thorough examination of large sample populations is time and labor intensive. Recently, it became possible to measure mutant frequencies in T lymphocytes; one method is a colony assay at the HPRT gene, and the other is a flow-cytometric assay at the T-cell-receptor (TCR) gene. To test for the possible use of these mutation assays, concurrent measurements were taken on blood samples from women who previously received a full course of radiation therapy for gynecological cancer. The results showed that the frequency of TCR mutants correlated reasonably well with that of dicentric chromosomes, whereas the frequency of HPRT mutants did not. Possible uses of the TCR mutation assay in combination with the conventional chromosome analysis or micronucleus assay after exposure of a relatively large population are discussed.
INTRODUCTION
With the increasing awareness of the importance of environmental factors in the develop ment of human cancers, biological monitoring of exposure to various mutagens and carcinogens has become a public-health, as well as a scientific, issue. From the classic epidemiological viewpoint, biomonitoring provides a quantitative link between cause and effect and thus enables mutagen/carcinogen dose evaluations that are useful for risk assessment of future manifestations of neoplasia. Accordingly, because of public concern as well as the investigational scientific merits regarding carcinogenesis, mutagenesis, and teratogenesis, a risk factor suitable as a biomonitor ing model is ionizing radiation. Because occupational radiation exposure is strictly regulated, nonmedical exposures are usually accidental, and hence dose evaluation is generally difficult. In this regard, biomonitoring systems that use easily obtainable somatic cells would be preferable, and chromosome analysis in peripheral-blood lymphocytes has long been used for this purpose. Unstable-type aberrations (primarily dicentrics and rings) are good markers because of their ease of detection and low background frequency (approximately 0.1%). Radiation exposure causes a dose-dependent increase in aberration frequency; studies using this assay system have reported similarities in radioresponse of lymphocytes irradiated in vitro and in vivol-4). Moreov er, in vitro exposure of Go lymphocytes to most chemical mutagens produce uniquely chromatid type aberrations, whereas only ionizing radiation and some radiomimetic chemicals (e.g., bleomycin) are capable of producing chromosome-type aberrations Such differences can be exploited using chromosome aberration assays to discriminate between radiation and chemical exposure effects. Thus, despite the decay of their frequency following exposure, unstable-type chromosome aberrations still retain wide utility for assessment of radiation dose. Stable-type aberration (translocations and inversions) frequencies do not decrease with time, but detection requires special skills, and objective scoring is difficult. A recently developed fluorescence-in situ-hybridization technique would be useful in this regard
Since the discovery of interleukin-2, a T-cell growth factor, a long-term culture of peripher al-blood lymphocytes became possible, and assay conditions for the measurement of the in vivo mutant frequency (Mf) at the hypoxanthine phosphoribosyltransferase (HPRT) locus were developed9,10 The assay was used for detection of increased Mf in patients receiving radioim munoglobulin therapy'1"2 or breast-cancer patients receiving radiotherapy13,14) When it was applied to the atomic-bomb survivors, a statistically significant, but weak, increase of Mf with dose was observed (ref. 15 and Hirai et al., in preparation). The lymphocyte HPRT assay has been reported to be a potentially useful biological dosimeter of human exposure to environmen tal mutagens such as cigarette smoke'6-18>
As a second somatic mutation assay in lymphocytes, a flow-cytometric technique for detection of mutant lymphocytes deficient in the T-cell receptor (TCR) was recently developed in our laboratory19)
The TCR is a heterodimer comprising a and /9 or y and s chains and is associated with a molecular complex referred to as the CD3 antigen, a differentiation antigen expressed on the surface of mature T lymphocytes. Only one of the two alleles for the TCR gene is expressed in the majority of T cells by allelic exclusion; therefore, TCR genes are functionally hemizygous though autosomally located. For the TCR molecules to be expressed on the T-cell surface, the complete CD3/TCR complex is required. Thus any defect on one of the two molecules that make up the TCR heterodimer results in a loss of CD3 surface expression19>
The principle of the assay is to label lymphocytes with fluorescently tagged anti-CD3 and anti-CD4 antibodies to detect rare CD3 4+ cells among CD3+4+ normal helper/inducer T cells. Our preliminary results showed that for radiotherapy patients CD3-4+ frequency declined posttreatment with a half-life of approximately 2 years20), slightly longer than the half-life in unstable-type chromosome aberration frequencies for ankylosing spondylitis patients and radiotherapy patients reported by Buckton et all). and Norman et al21), respectively.
The present study was intended to compare these three bioassays using the same blood samples from each respective radiotherapy patient when possible.
MATERIALS AND METHODS

Blood samples
Peripheral-blood samples were obtained from 44 women who had undergone a full course of radiation therapy by linear-accelerator X rays for uterine or cervical cancer. Ideally all 44 samples were to be tested for chromosome aberrations, TCR mutants, and HPRT mutants. However lack of sufficient amount of blood, logistical problems, or differences of the onset of each study prevented concurrent assays for all the samples. Consequently, among the 44 blood samples, 12 were measured by only one of the three assays (4 for HPRT mutants, 7 for TCR mutants, and 1 for chromosome aberrations), 13 by two assays (11 for HPRT and TCR mutants, and 2 for TCR mutants and chromosome aberrations) and 19 by the three assays. The total doses ranged from 50 to 60 Gy were usually given in 2-Gy daily fraction, five days a week, for five to six weeks. The time of sampling following the last 2-Gy fraction varied from one to 93 months. The donor ages ranged from 40 to 76 years.
Unstable-chromosome-aberration assay
The heparinized blood from 22 patients was centrifuged, and the plasma and buffycoat layers were saved. Cultures were set up by resuspending the buffy-coat cells in a medium consisting of RPMI 1640, 10% fetal bovine serum, 5% autologous plasma, and 1% PHA. Colcemid was added during the last 3 of a 72-hr culture. Metaphase spreads were prepared on pre-cleaned slides and stained with Giemsa. Dicentric and fragment frequencies were counted in 100 metaphases.
To achieve a higher mitotic index, lymphocytes were cultured 72 hr for chromosome analysis to compensate for the limited amount of blood available. A long culture time of in vitro irradiated lymphocytes results in a decreased frequency of unstable chromosome aberrations. Results for 48-hr culture of three patients gave dicentric frequencies of 14, 26, and 34% (average of 25%) within 6 months after the therapy (Umeki et al., manuscript in preparation). Compared with these values, the current data showed an initial dicentric frequency of about 10% ( Fig. 1) , suggesting that the present results are underestimated by a factor of 2 to 3. In vitro data suggest that the average dicentric frequency of 25% mentioned above corresponds to about 2 Gy for linear-accelarator X rays 22). This is in accord with the observation that dicentric frequency decreased to 1/3 and 1/2 when culture time was extended from 48 hr to 72 hr after 1.5 Gy and 4 Gy of X-ray exposure in vitro, respectively 23). Although this is an important drawback of the present data, one can postulate that the underestimation may operate to reduce, but not to artifactually increase, the correlations between various biological endpoints, and hence the conclusion should not be seriously endangered by this particular problem.
TCR mutation assay
Measurement of TCR Mf has been described previously". Briefly, lymphocytes from 39 patients were isolated by Ficoll-Hypaque gradient centrifugation and incubated on ice for 30 minutes with phycoerythrin-labelled anti-Leu4 (CD3) and fluorescein-isothiocyanate-labelled anti-Leu3 (CD4) monoclonal antibodies. After being washed, the cell suspensions were analyzed by flow cytometry (FACScan, Becton-Dickinson Immunocytometry Systems, San Jose, CA, USA). The TCR Mf was calculated as the proportion of CD3-4+ cells in the total counted CD4+ population, as described previously19>
HPRT mutation assay Peripheral-blood mononuclear cells (PBMCs) from 34 patients were plated into 96-well microtiter plates (flat bottom, Costar, Cambridge, MA, USA) at an average of 1 cell/well and 5 X 104 cells/well for nonselective and 6-thioguanine-selective plates, respectively. As feeder cells, Raji cells (human Burkitt's lymphoma) were seeded to both plates at 1 X 104 cells/well after 100 Gy of X-irradiation. Allogeneic PBMCs exposed to 50 Gy of X rays were also added to nonselective plates (5 X 104 cells/well). Selective plates contained 2.5 ug/ml of 6-thioguanine, and one plate was used for selective and nonselective lymphocytes for each patient.
The culture medium consisted of MEM alpha without nucleosides (Gibco, Grand Island, NY, USA) supplemented with 24-mM HEPES, antibiotics, 2-mM L-glutamine, 10%heat inactivated fetal calf serum, 1% heat-inactivated human serum, and 0.2-ng/ml recombinant human interleukin-2 (a gift from Takeda Pharmacy, Osaka, Japan). Colony growth was determined 2 weeks after incubation, and cloning efficiency was determined by the fraction of negative wells, as described previously9,10 Mutant frequency was calculated as a ratio of cloning efficiency in the selection plate to that in the nonselection plate. Figure 1 shows the frequency of dicentric chromosomes post radiation therapy. Although it varied considerably among the patients, the frequency was generally high for about 20 months post therapy (except for one unusually low case), intermediate from 20 to 50 months, and low thereafter. Figure 2 shows a plot similar to Figure 1 , of the TCR Mf. Here too, a considerable variation among individuals is apparent. Some of the cases measured within 10 months after the therapy should be regarded as having not yet reached their peak values due to an insufficient time for the expression of the mutant phenotype. Elevated Mfs were observed until about 40 months, after which they seemed to decline gradually to reach the background level. The half-lives of the two types of mutants appear to be similar at roughly 2 to 3 years. Figure 3 shows the results for the HPRT Mf. Contrary to the above 2 sets of results, the increase in the HPRT Mf is less impressive, and, consequently, the frequency, is less dependent on the posttreatment period. Because of the large scatter from 0 to 30 months, a decreasing trend of the frequency is difficult to see and even a rough derivation of the HPRT Mf is difficult without extensive uncertainties. After 30 months, the frequency appears to reach a constant level, at about 5 X 10-6, which is close to the level of normal people. The frequencies of chromosome aberrations versus TCR and HPRT mutants are presented in Figures 4 and 5 , respectively. The relationship between dicentrics and TCR mutation frequencies was statistically significant (p<0.001), and correlation was reasonably good (r = 0.83).
RESULTS
In contrast, the correlation between dicentrics and HPRT mutants is less impressive. Although the p-value was less than 0.01, interpretation of the results requires caution. The R2 coefficient of 0.35 indicates the weakness of the correlation. In fact, the p-value for the existence of positive correlation is highly dependent on a few influential observations. For example, removal of one such point, (ie, highest value for both HPRT Mf and dicentric yield) raises the p-value from less than 0.01 to 0.13. Thus, the p-value of less than 0.01 cannot be taken as strong evidence for correlation. 
DISCUSSION
Possible mechanisms for the nonconformity of HPRT Mf Surprisingly, although there are clear increases in the frequencies of both TCR mutants and dicentric yields, the average HPRT Mf is only twice the background frequency (Figs . 1-3 ). This probably results because the HPRT mutants must be capable of forming colonies to be detected. Since the dose distribution of the lymphocyte population is heterogeneous, and repeatedly irradiated cells are largely incapable of forming colonies, the contribution of high-dose cells to the total Mf is small, even though such cells do express higher frequency of mutational damage . In addition, there is always a fraction of cells that escape any radiation exposures, and these cells constitute an unduly larger fraction among the surviving colonies.
Ekstrand et al., developed a model of lymphocyte kinetics in radiotherapy patients24,2s) Assuming that 28.5% of the total lymphocytes are in gut-associated lymphatic tissues and in the mesenteric nodes; that at any one time 25% of these lymphocytes are in the radiation field of the pelvic region during uterine cancer treatment; and that 40% of the cells receiving 2 Gy die by interphase death, they estimated that the fraction of cells that received N times the fractionated 2-Gy exposure but escaped interphase death after the whole course of radiotherapy (30 times A similar doubling in HPRT after radiotherapy was reported for patients with breast cancer, although the total dose was 45 Gy in most of these cases 14) In contrast, detection of TCR mutants or unstable chromosomal changes requires only survival from interphase death. Since 2 Gy of linear-accelerator X rays causes dicentrics at a frequency of 0.25/cell in vitro22), the calculated dicentric yield based on the above model is 1 4 0.42 E O F (N) X 0.25 N= 0.30, which is close to the average frequency of 0.25 measured under 48-hr culture conditions (see Materials and methods section). Thus, the model reasonably describes the complicated kinetics of lymphocytes during the therapy. The results imply that the HPRT assay would work better in whole-body irradiation cases (e.g., radioimmunotherapy of cancer) but not in partial-body high-dose irradiation cases. In contrast, the TCR assay or chromosome analysis would work in both cases for biological dose estimation.
Estimation of minimum detectable doses
For the estimation of minimum detectable doses, unfortunately, not enough information is available for the parameters that describe the characteristics of the TCR or chromosome assay in terms of the measurement errors and the variation in the dose response among individuals. Thus, for the sake of simplicity, we assume here that no individual variations exist in the dose response and that the measurement error is negligible compared with the variation in the background frequency among individuals.
According to the results for non-exposed people, the average frequency of TCR mutants increases with donor age19). The 95th percentiles of Mfs (Mfo .95) of each age group were 3.7 X 10-4 for 20 39 year olds (n = 33), 4.3 X 10-4 for 40 59 (n = 50), and 5.8 X 10-4 for 60 80 or more (n = 39) when log-transformed Mfs were used for the estimation. If these values were provisionally taken as age-related discrimination levels, 4 cases out of 21 examined in the present study would be false negatives, that is, apparently normal TCR Mf but with a dicentric frequency of 1% or higher. Thus, the detection rate is about 80%.
In vitro data for the induction of TCR mutants provided a dose-response relationship of y = 6.2D2 + 7.3D, where y is Mf in 10-4 and D is X-ray dose in Gy (Umeki et al., in preparation). Thus, the X-ray doses required to move the Mf distribution upward by Mfo.95 of the background frequencies are 0.37, 0.43, and 0.54 Gy for age groups of 20 39, 40 59, and 60 80 or more, respectively. In other words, people who received radiation doses larger than these values are expected to show TCR Mfs higher than the Mfo .95 of the age-matched control group under the assumption mentioned above. As for the chromosome aberrations, an average frequency of 0.89 X 10-3 is obtained for dicentrics plus rings in lymphocytes from normal people collected from various data sets27). Although the lowest detectable dose is essentially a function of the number of cells scored, from the viewpoint of cost and benefit, examination of 100 metaphases for each blood sample would be a reasonable compromise. Under such conditions, a detection rate of 80%, as suggested for the TCR assay in the present study, would be attained when the true aberration frequency is 1.6% (i.e., probability of false negative is (1 0.016)100 = 0.20). In vitro data suggest that the dose to induce a 1.6% frequency of dicentrics plus rings is about 0.25 Gy for 200-kVp X rays22). Although chromosome aberration frequency increases with donor age as in TCR Mf, the minimum detectable dose is much less influenced by age in the chromosome assay since the background frequency of dicentrics and rings is far below 1.6%, even among the elderly28). These estimations are preliminary, but under a similar level of detection rate, the minimum detectable dose appears to be about 2 times lower in chromosome tests than in the TCR assay.
The labor required for these analyses is another issue. Ten to 20 samples per day can be tested for TCR Mf by one technician, whereas about 200 metaphases can be microscopically examined for dicentrics in the same time. If an automated metaphase-searching system were to assist in the visual analysis, then examination of 1500 to 2000 metaphases may be possible (AA Awa, personal communication). In this regard, the two assays would be equally powerful.
Comparison of other factors
Although the TCR assay has a potential for rapid screening, the mutants appear to take from 6 months to one year to manifest their highest Mf (Umeki, unpublished observation). This is in sharp contrast to the chromosome aberration or micronucleus frequency, which manifest the full phenotype immediately after the radiation exposure. Thus, the TCR assay is not advantageous over the mentioned cytogenetic methods for probably 6 months to one year after the exposure.
For the erythrocyte glycophorin A (GPA) assay29,30>, no estimation has yet been possible for the lag time between radiation exposure and full manifestation of the mutant phenotype. In this case, the target cells are bone-marrow stem cells at various stages of differentiation. Because mature erythrocytes have a lifespan of about 120 days, at least 4 months would be required for the erythrocytes preexisting the exposure to disappear from the peripheral blood. One drawback to the GPA assay is its lack of appropriate models among radiotherapy patients. During external-beam radiotherapy, the bone marrow in the radiation field receives a dose too high to bear evidence for the increase in Mf among the patients. For systemic 1311-treatment cases, the increase is detectable but not extensive, and estimation of the lag time is still difficult (Umeki et al., manuscript in preparation).
Micronucleus frequency is simple to measure, but one serious drawback is that the spontaneous frequency greatly varies, i.e., from 2% to 10%, among those aged 40 years or more 31). Since an in vitro study showed that a 0.5-Gy exposure, for example, resulted in induction of about 4% micronucleated cells, it would be prudent not to rely totally upon micronucleus data for biologic dosimetry but to look at chromosome aberrations as well, especially when the estimated doses are below 1 Gy and the examinees are more than 40 years old.
In conclusion, each biologic method for dose estimation has its respective merits and demerits, and, consequently, these methods may be more useful in combination. Such an approach will provide better information for dose evaluation.
